Navigation Links
AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Date:11/12/2010

REDWOOD CITY, Calif., Nov. 12, 2010 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company.

Piper Jaffray & Co. is acting as sole book-running manager. Canaccord Genuity Inc., Cowen and Company, LLC and JMP Securities are acting as co-managers for the offering. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Piper Jaffray & Co., 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, Telephone 1-800-747-3924.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 ... ... US$ 7,167.6 Mn in 2015, and is expected to reach ... 5.6% from 2016 to 2024. The global ...
(Date:4/19/2017)... 2017 Cardiology devices segment is anticipated to reach ... The Cardiology Devices segment is likely to create absolute $ ... 2018 over 2017. By the end of 2027, Cardiology Devices ... US$ 700 Mn, expanding at a CAGR of 18.4% over ... Asia Pacific reprocessed medical devices market in ...
(Date:4/19/2017)... Tenn. and DALLAS , April 19, 2017 ... announced that the first patients in Nashville ... device in the Lower Esophageal Sphincter Stimulation for GERD ... implantable device designed to provide long-term reflux control by ... GERD affects nearly 65 million people in ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... and advanced nutraceutical supplements, through its Nova Skin Sciences division, recently announced the ... of a moisturizer with the power of an anti-aging concentrate. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Semrock’s highly popular ... premier online modeling resource for fluorescence microscopists and optical system designers, enabling The ... 5 years spanning the globe, SearchLight has become a tremendously popular tool for ...
(Date:4/27/2017)... ... 27, 2017 , ... The Incentive Research Foundation is pleased ... Guide," a groundbreaking analysis of how behavioral economics can be applied to the ... IRR programs, the report highlights proven behavioral economics approaches and the powerful role ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... husband Dan Gasby the 2017 Public Leadership in Neurology Award (PLINA). The couple ... professional athlete Tedy Bruschi, Vice President Walter Mondale, actor Michael J. Fox and ...
Breaking Medicine News(10 mins):